← All trials
NCT00331188
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2006
- Primary completion
- Jun 1, 2008
- Completion date
- Jul 1, 2008
- First posted
- —
- Last posted
- —
- Enrollment
- 70
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- DebiopharmLead sponsor
- University of California, San DiegoOverall official - principal investigator
- University of Colorado, DenverOverall official - principal investigator
- Virginia Commonwealth UniversityOverall official - principal investigator
- Northwestern UniversityOverall official - principal investigator
- Medical University of South CarolinaOverall official - principal investigator
- Harvard UniversityOverall official - principal investigator
- Mayo ClinicOverall official - principal investigator
- Johns Hopkins UniversityOverall official - principal investigator
- Cornell UniversityOverall official - principal investigator
- Indiana UniversityOverall official - principal investigator
- University of KentuckyOverall official - principal investigator
- Alabama Liver & Digestive Specialists Research CenterOverall official - principal investigator
- Yale UniversityStudy chair
- CHRISTUS HealthOverall official - principal investigator
- Washington University in St. LouisOverall official - principal investigator
- Mission Health, North CarolinaOverall official - principal investigator
- University of Alabama, BirminghamOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.